FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person * Mann Brenda				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) VP of Research & Development					
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 02/04/2020							/Year)		VP of Re	search & De	velopment			
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)							/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City	')	(State)	(.	(Zip)			Ta	ble I	- Non	-Deri	vative S	Securities	Acqui	ired, Dispo	osed of, or I	Beneficially (Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		f Code (Instr. 8)		ction 4. Securities Acq (A) or Disposed o (Instr. 3, 4 and 5)		of (D)	or Indirect		7. Nature of Indirect Beneficial Ownership (Instr. 4)					
								С	ode	V	Amoun	(A) or (D)	Price				(I) (Instr. 4)	
Common Stock 02/04/2020			/2020				F	(1)		109	D	\$ 6	10,898			D		
				Table II - D					quire	conta the fo	ained in orm dis sposed o	n this for splays a of, or Ben	rm are curre eficial	not requesting ntly valid		ormation spond unlead rol number	ss	1474 (9-02)
1. Title of	2.	3. Transaction	n 3A	A. Deemed	· ·	uts, call 4.	s, wa	rran 5.			convert te Exerc	ible secu		itle and	8 Price of	9. Number o	of 10.	11. Natu
	Conversion or Exercise Price of Derivative Security	Date (Month/Day/	Year) Execution any	xecution Dat	e, if Transaction Code (ear) (Instr. 8)				and Expiration Date (Month/Day/Year)			Amo Und Secu	ount of erlying urities cr. 3 and	Derivative Security (Instr. 5)		Owners Form of Derivat Security Direct (or Indir	hip of Indire Benefic Owners (Instr. 4	

Reporting Owners

	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Mann Brenda C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Research & Development				

Signatures

/s/ Sarah Romano, Attorney-in-Fact*	02/05/2020		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 02/01/2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.